Sanofi Q3 2026 Earnings Recap

Sanofi’s shares rose 5.6% after earnings, as Q3 sales grew 14.3% to €14.4 billion. The company also reaffirmed its focus on growth through Dupixent’s loss of exclusivity, backed by expanded Regeneron collaboration and planned business development.

Key Takeaways

• Sanofi reported Q3 sales of €14.4 billion, up 14.3% year over year.
• Management named immunology, rare diseases, and vaccines as its strategic focus areas.
• Sanofi discontinued amlitelimab and itepekimab as part of pipeline optimization.
• The expanded Regeneron alliance adds access to four immunology compounds; Sanofi aims to launch a long-acting anti-IL-13 for atopic dermatitis ahead of Dupixent biosimilars.
• Management expects Dupixent’s loss of exclusivity to affect group revenue only moderately, while prioritizing preservation of earnings and cash flow.